Home > News > Erratum to: Cytogenetic, Inflammatory, Immunologic, and Infectious Basis for Dysplastic Hematopoeisis
Immunotherapy
Read Time: < 1 min

Erratum to: Cytogenetic, Inflammatory, Immunologic, and Infectious Basis for Dysplastic Hematopoeisis

Published Online: February 20th 2018 Oncology & Hematology Review, 2017;14(1):[online only]
Authors: Pedro Alcedo, Enrique Andrade, Hussein Hamad, Gustavo Rivero
Quick Links:
Article
Article Information
Article:

In the originally published article there was an error in the abbreviations for Figure 1. The abbreviation “MEP” was incorrectly defined as “monoethyl phospohate”; this should read “megakaryocytic erythroid progenitor”.

Article Information:

Further Resources

Share this Article
Related Content In Immunotherapy
Immunotherapy
Emerging Targeted and Immunotherapies in Cholangiocarcinoma
Shiraj Sen, Rachna T Shroff Read Time: 9 mins

Oncology & Hematology Review (US). 2019;15(2):71–5

Cholangiocarcinoma is an epithelial malignancy of the biliary system characterized by cholangiocyte differentiation, and its incidence is on the rise. Currently, cholangiocarcinomas are classified by their anatomical location in the biliary system as intrahepatic cholangiocarcinoma, distal cholangiocarcinoma, or hilar cholangiocarcinoma. Since 2010, the standard of care in all advanced, inoperable biliary tract cancers has been combination […]

Immunotherapy
PARP Inhibitors may be Beneficial in a Broader Range of Patients
W Lee Kraus Read Time: 3 mins

Oncology & Hematology Review (US). 2019;15(2):66–7

Q. What is the role of PARP-1 in the pathogenesis of cancer? PARP-1 is a protein that resides in the cell nucleus where it plays a role in most, if not all, nuclear functions (e.g. DNA repair, transcription, RNA processing, RNA ribosomal transcription). PARP-1 uses these pathways to assist the cancer cell in its uncontrolled […]

Immunotherapy
Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy – the PSV™ Platform
Paisley Myers Read Time: 4 mins

Oncology & Hematology Review (US). 2019:15(2):64–5

Q. What are phosphopeptide tumor targets and why are they good candidates for vaccine and cell therapy development? PTTs are a novel class of neoantigen. They are portions of aberrantly phosphorylated proteins that are presented at the cell surface to the immune system in the context of human leukocyte antigen (HLA) class I molecules. These […]

Trending In Immunotherapy:

Emerging Targeted and Immunotherapies in Cholangiocarcinoma
Immunotherapy
    • More Actions
    Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72